'We're not doing 30 bets a year': Vijay Pande on betting small after running $4B at a16z
Vijay Pande — who left a16z's roughly $4 billion biotech practice last year to start the much smaller, AI native VZVC — talks about why biology is finally shifting from a "discovery" science to an "engineering" one, why clinical trials are still brutally expensive, and why he thinks open, shared ...
Connie Loizos科技新星日报
1 分钟阅读0 阅读
Vijay Pande — who left a16z's roughly $4 billion biotech practice last year to start the much smaller, AI-native VZVC — talks about why biology is finally shifting from a "discovery" science to an "engineering" one, why clinical trials are still brutally expensive, and why he thinks open, shared datasets (not walled-off ones) are what will actually let AI transform medicine.
Source: TechCrunch AI — fetched automatically.